

Author: Weiss Johanna
Publisher: Springer Publishing Company
ISSN: 0028-1298
Source: Naunyn-Schmiedeberg's Archives of Pharmacology, Vol.378, Iss.3, 2008-09, pp. : 275-282
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Tilidine is one of the most widely used narcotics in Germany and Belgium. The compound's active metabolite nortilidine easily penetrates the blood-brain barrier and activates the μ-opioid receptor. Thus far, the enzymes involved in tilidine metabolism are unknown. Therefore, the aim of our study was to identify the cytochrome P450 isozymes (CYPs) involved in N-demethylation of tilidine in vitro. We used human liver microsomes as well as recombinant CYPs to investigate the demethylation of tilidine to nortilidine and quantified nortilidine by liquid chromatography-tandem mass spectrometry. Inhibition of CYPs was quantified with commercial kits. Moreover, inhibition of ABCB1 and ABCG2 was investigated. Our results demonstrated that N-demethylation of tilidine to nortilidine followed a Michaelis-Menten kinetic with a
Related content


By Pan Yan Tiong Kai Abd-Rashid Badrul Ismail Zakiah Ismail Rusli Mak Joon Ong Chin
Journal of Natural Medicines, Vol. 68, Iss. 2, 2014-04 ,pp. :


By Brown Hayley S. Galetin Aleksandra Hallifax David Houston J. Brian
Clinical Pharmacokinetics, Vol. 45, Iss. 10, 2006-01 ,pp. :


Influence of CYP2D6 Genetics on Opioid Kinetics, Metabolism and Response
Current Pharmacogenomics, Vol. 3, Iss. 1, 2005-03 ,pp. :

